DrugPatentWatch Database Preview
Drugs in Development Information for RPL554
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug RPL554?
RPL554 is an investigational drug.
There have been 10 clinical trials for RPL554.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2015.
The most common disease conditions in clinical trials are Lung Diseases, Pulmonary Disease, Chronic Obstructive, and Lung Diseases, Obstructive. The leading clinical trial sponsors are Verona Pharma plc, Iqvia Pty Ltd, and LGC Limited.
There are eleven US patents protecting this investigational drug and one hundred and seventy-four international patents.
Summary for RPL554
| US Patents | 11 |
| International Patents | 174 |
| US Patent Applications | 26 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2015-04-01) |
| Vendors | 7 |
Recent Clinical Trials for RPL554
| Title | Sponsor | Phase |
|---|---|---|
| Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | IQVIA | Phase 2 |
| Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | LGC Limited | Phase 2 |
| Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | Verona Pharma plc | Phase 2 |
Clinical Trial Summary for RPL554
Top disease conditions for RPL554
Top clinical trial sponsors for RPL554
US Patents for RPL554
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RPL554 | Start Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | Start Trial |
| RPL554 | Start Trial | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | Start Trial |
| RPL554 | Start Trial | Derivatives of pyrimido[6.1-a]isoquinolin-4-one | Vernalis Limited (Berkshire, GB) | Start Trial |
| RPL554 | Start Trial | Derivatives of pyrimido[6,1-a]isoquinolin-4-one | Rhinopharma Limited (British Columbia, CA) | Start Trial |
| RPL554 | Start Trial | Derivatives of pyrimido[6, 1-A]isoquinolin-4-one | Verona Pharma PLC (London, GB) | Start Trial |
| RPL554 | Start Trial | Derivatives of pyrimido[6,1-A]isoquinolin-4-one | Verona Pharma plc (London, GB) | Start Trial |
| RPL554 | Start Trial | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound | Verona Pharma plc (London, GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RPL554
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RPL554 | Argentina | 099177 | 2034-01-24 | Start Trial |
| RPL554 | Australia | 2015208932 | 2034-01-24 | Start Trial |
| RPL554 | Australia | 2017200338 | 2034-01-24 | Start Trial |
| RPL554 | Australia | 2018202956 | 2034-01-24 | Start Trial |
| RPL554 | Australia | 2019202675 | 2034-01-24 | Start Trial |
| RPL554 | Canada | 2935625 | 2034-01-24 | Start Trial |
| RPL554 | Chile | 2016001889 | 2034-01-24 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
